Download MendeleyNovel thrombin inhibitors that are based on a macrocyclic tripeptide motif
Greco, M.N., Powell, E.T., Hecker, L.R., Andrade-Gordon, P., Kauffman, J.A., Lewis, J.M., Ganesh, V., Tulinsky, A., Maryanoff, B.E.(1996) Bioorg Med Chem Lett 6: 2947-2952
- PubMed: 8367461
- DOI: https://doi.org/10.1073/pnas.90.17.8048
- Primary Citation of Related Structures:
1AY6, 1TMB - PubMed Abstract:
The macrocyclic peptide cyclotheonamide A (CtA), isolated from the marine sponge Theonella sp., represents an unusual class of serine protease inhibitor. A complex of this inhibitor with human alpha-thrombin, a protease central to the bioregulation of thrombosis and hemostasis, was studied by x-ray crystallography. This work (2.3-A resolution) confirms the structure of CtA and reveals intimate details about its molecular recognition within the enzyme active site. Interactions due to the "Pro-Arg motif" (Arg occupancy of the S1 specificity pocket; formation of a hydrogen-bonded two-strand antiparallel beta-sheet with Ser214-Gly216) and the alpha-keto amide group of CtA are primarily responsible for binding to thrombin, with the alpha-keto amide serving as a transition-state analogue. A special interaction with the "insertion loop" of thrombin (Tyr60A-Thr60I) is manifested through engagement of the hydroxyphenyl group of CtA with Trp60D as part of an "aromatic stacking chain." Biochemical inhibition data (Ki values at 37 degrees C) were obtained for CtA with thrombin and a diverse collection of serine proteases. Thus, CtA is just a moderate inhibitor of human alpha-thrombin (Ki = 0.18 microM) but a potent inhibitor of trypsin (Ki = 0.023 microM) and streptokinase (Ki = 0.035 microM). The relative lack of potency of CtA as a thrombin inhibitor is discussed with respect to certain structural features of the enzyme complex. We also report the total synthesis of CtA, by a convergent [2 + 3] fragment-condensation approach, to serve the preparation of cyclotheonamide analogues for structure-function studies.
Organizational Affiliation:
Drug Discovery Division, R. W. Johnson Pharmaceutical Research Institute, Spring House, PA 19477.
